Factors Associated With Single-Surgery Anatomical Success After Pars Plana Vitrectomy in Inferior Rhegmatogenous Retinal Detachment.

Authors

Amine Habib, Nour Boungab, Karine Lagrené, Maxime Wack, Sarah Ayello-Scheer, Francine Behar-Cohen, Pierre-Olivier Barale, Stéphane Bertin, Aliénor Vienne-Jumeau

Published in

Retina (Philadelphia, Pa.). Sep 21, 2026. Epub Sep 21, 2026.

Abstract

To evaluate associations between retinopexy modality, surgical and anatomical factors, and single-surgery anatomical success (SSAS) after pars plana vitrectomy (PPV) for primary inferior rhegmatogenous retinal detachment (RRD).
This retrospective single-center cohort included consecutive eyes undergoing PPV for primary inferior RRD with at least 3 months of follow-up. The primary outcome was SSAS, defined as absence of redetachment during follow-up and at least 2 months after silicone oil removal when applicable.
Among 235 eyes, median follow-up was 8 months. SSAS was achieved in 175 eyes (74.5%), while 60 eyes (25.5%) redetached at a median of 35 days. SSAS was 83.3% with endolaser, 74.6% with combined retinopexy, and 64.6% with cryotherapy (p = 0.021). In multivariable analysis, endolaser was associated with lower odds of failure compared with cryotherapy (OR 0.21, 95% CI 0.09-0.48; p = 0.00037), while combined retinopexy was associated with intermediate odds of failure (OR 0.39, 95% CI 0.15-0.95; p = 0.043). Compared with PVR grade A, grade B (OR 5.19, 95% CI 2.30-12.37; p = 0.00011) and grade C (OR 10.60, 95% CI 4.15-28.84; p < 0.00001) were associated with higher odds of anatomical failure. A causative break at 6 o'clock was also associated with higher odds of failure (OR 4.61; p = 0.005).
In PPV for inferior RRD, endolaser retinopexy was associated with significantly higher anatomical success than cryotherapy, with combined treatment yielding intermediate outcomes. No significant association was observed between anatomical outcome and tamponade choice or PFCL use.

PMID:
42765885
Bibliographic data and abstract were imported from PubMed on 21 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.